ImmuneOnco is enlisted in‘’2021 National Top 100 Excellence in Innovation of Seed Pharmaceutical Enterprises in China‘’
Dec. 21, 2021, Shanghai, China.
The list of ‘2021 National Top 100 Excellence in Innovation of Seed Pharmaceutical Enterprises in China’ was made public today. ImmuneOnco was successfully selected for the name of the list and it is highly recognized for its outstanding performance and development potential in the field of new drug R&D.
ImmuneOnco is committed to R&D of anti-tumor immunotherapy including new recombinant proteins, bispecific antibodies, and TANK™ cell therapy. At present, there are several new anti-tumor drugs in the clinical stage of development. So far, ImmuneOnco has received total 11 clinical approvals for 5 projects (9 in China and 2 in the United States).
By 2021, ImmuneOnco has set up multiple developmental pipelines such as IMM01 (CD47), IMM0306 (CD47/CD20), IMM2510 (VEGF/PD-L1), IMM2902 (CD47/Her2), IMM27M (CTLA-4) and makes promising progress. While product R&D is advancing rapidly, ImmuneOnco's wholly-owned subsidiary, ImmuneOnco Biopharm (Shanghai) Co., Ltd., was established. It will accelerate the development of drug candidates in pipelines, actively promote clinical trials of key products and strive for an early market approval so as to benefit cancer patients around the world.
ImmuneOnco is also building biopharmaceutical factory, an antibody drug manufacturing facility with high automation, information management compatibility and international GMP standards.
Dr. Tian Wenzhi, founder and chairman of ImmuneOnco, said:
About "2021 National Top 100 Excellence in Innovation of Seed Pharmaceutical Enterprises in China "
The "2021 National Top 100 Excellence in Innovation of Seed Pharmaceutical Enterprises in China " list follows the selection system of "Three Dimensions and Four Indicators", screening out 100 potential seed companies that have the potential to become "Top 100 Chinese Pharmaceutical Innovation Companies" and those Innovative enterprise have not been publicly listed on stock markets by October 21, 2021)
Founded in June 2015 in the Zhangjiang Hi-Tech Park of the China (Shanghai) Pilot Free Trade Zone, ImmuneOnco focuses on the development and research of anti-tumor immunotherapy products, including bi-specific antibodies, novel recombinant proteins, and TankTM cellular therapy. The common feature of these products is to activate the patient's own immune system to exert the anti-tumor effects, and ultimately inhibit the endless growth of tumor cells and reverse the malignant symptoms, so that the patients gradually return to healthy. So far, several new anti-tumor drugs are in clinical research stage. ImmuneOnco is recognized by authorities as one of the ‘Top 50 Start-up Enterprises with the Most Investment Potential in Shanghai’ in 2016, the "Excellent Enterprise" in the 2017 China Innovation and Entrepreneurship Competition, and the "Enterprise Excellence Award" of Shanghai Science and Technology Entrepreneurship in 2017.